Viral Infections and Antiviral Therapies provides comprehensive coverage of viral infections and their transmission. Coverage includes antiviral agents, therapeutics, their mechanisms and treatment strategies. The book is organized into four sections, including an introduction to antiviral therapies, viral infections and their transmission, antiviral agents and therapeutics, and a market overview and future developments. The chapters in each section of the book discuss various key topics that are contributed to by an international group of leading experts.
Section I: Introduction 1. Introduction to antiviral therapy
Section II: Viral infections and transmission 2. Emerging viral diseases 3. Evolution and transmission of viruses 4. Mode of viral infections and transmissions 5. Transmission and Intervention Dynamics of SARS-CoV-2 6. Sexually transmitted viral infections 7. Testing of viral infections 8. Electron microscopic methods for virus diagnosis
Section III: Antiviral agents and therapeutics 9. Virotherapy 10. Challenges in designing antiviral agents 11. Anti-influenza agents 12. Anti-herpes virus agents 13. Antiretroviral Therapies 14. Rotavirus and anti-rotaviral agents: Trends and advances 15. Current therapeutic strategies and novel antiviral compounds for the treatment of non-polio enteroviruses 16. Antiviral agents against flaviviruses 17. Pathophysiology of HIV and strategies to eliminate AIDS as a public health threat 18. Herbal drugs to combat viruses 19. Strategies for delivery of antiviral agents 20. Nanovesicles for delivery of antiviral agents 21. Antiviral biomaterials 22. Antiviral biomolecules from marine inhabitantsBalasubramanian 23. Plant polysaccharides as antiviral agents 24. Antiviral peptides against dengue virus 25. mRNA vaccines for COVID-19 26. Immunotherapy as an emerging and promising tool against viral infections 27. Role of nutraceuticals as immunomodulators to combat viruses
Section IV: Others 28. In vitro and in vivo approaches for evaluating antiviral efficacy 29. Clinical trials and regulatory considerations of antiviral agents 30. Future perspectives of antiviral therapy